[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369372-105":59,"doc-detail-369372-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pan-cancer-clinical-and-molecular-landscape-of-mtap-deletion-in-nationwide-and-international-comprehensive-genomic-data-original-article","Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data - Original Article","","Pan-cancer retrospective analysis characterizes clinical and molecular profiles of MTAP-deleted tumors to support precision oncology strategies using PRMT5 inhibitors. Clinico-genomic data from the C-CAT database covering comprehensive genomic profiling in Japan (June 2019–November 2023) were used with machine learning and explainable AI to predict MTAP deficiency, then validated against TCGA and AACR GENIE datasets. MTAP deletion occurred in 9.6% overall, varied by cancer type, and correlated with distinct clinical features and actionable genomic contexts.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-clinical-and-molecular-landscape-of-mtap-deletion-in-nationwide-and-international-comprehensive-genomic-data-original-article/369372/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-clinical-and-molecular-landscape-of-mtap-deletion-in-nationwide-and-international-comprehensive-genomic-data-original-article/369372.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this pan-cancer study?","Question",{"text":112,"@type":113},"To comprehensively characterize the clinical and molecular profiles of MTAP-deleted tumors using nationwide and international comprehensive genomic datasets, enabling more precise PRMT5 inhibitor strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were MTAP deficiency predictors identified and validated?",{"text":117,"@type":113},"The study used machine learning and explainable AI on C-CAT clinico-genomic data, then validated and compared findings using TCGA and AACR GENIE datasets.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer types showed high prevalence of MTAP deletion?",{"text":121,"@type":113},"MTAP deletion was especially frequent in pancreatic cancer (18.4%), biliary tract cancer (15.6%), and lung cancer (14.3%).",{"name":123,"@type":110,"acceptedAnswer":124},"What biological and therapeutic rationale connects MTAP deletion to PRMT5 inhibitors?",{"text":125,"@type":113},"Loss of MTAP leads to accumulation of MTA that binds PRMT5 and disrupts PRMT5 activity; preclinical work suggests MTAP-deleted cells are especially vulnerable to PRMT5 inhibition, supporting synthetic lethal approaches.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369372,1790517718,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ORIGINAL ARTICLE  \nPan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data  \nH. Ikushima1􀀁, K. Watanabe1, 2, A. Shinozaki-Ushiku3, 4, K. Oda3 & H. Kage1  \n1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo; 2Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo; 3Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo; 4Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan  \nAvailable online xxx  \nBackground: Early-phase clinical trials of protein arginine methyltransferase 5 (PRMT5) inhibitors as synthetic lethal strategies have shown promising efﬁcacy in methylthioadenosine phosphorylase (MTAP)-deleted tumors. To reﬁne and expand this promising therapeutic approach within the framework of precision oncology, it is critical to comprehensively characterize the clinical and molecular proﬁles of MTAP-deleted tumors.  \nMaterials and methods: This pan-cancer retrospective cohort study analyzed clinico-genomic data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which includes 99.7% of patients who underwent comprehensive genomic proﬁling (CGP) in Japan between June 2019 and November 2023 . Machine learning and explainable artiﬁcial intelligence methods were applied to identify clinical predictors of MTAP deﬁciency. Findings were validated and compared using The Cancer Genome Atlas (TCGA) and American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) datasets.  \nResults: Among 51 828 pan-cancer patients in the C-CAT cohort, MTAP deletion was observed in 4964 cases (9 . 6%), with a high prevalence in pancreatic (18 .4%), biliary tract (15 . 6%), and lung (14 . 3%) cancers. MTAP deletion was associated with distinct clinical features, including male sex (56.0% versus 47.8%), older age (mean 62.4 versus 59.8 years), and shorter interval from diagnosis to CGP (median 380 .0 versus 567 .0 days) . In pancreatic cancer, MTAP deletion was more common in KRAS-mutant tumors (19 .8%) compared with KRAS wild-type tumors (8 .9%) . Across cancer types, MTAP deletion was less frequent in RB1-mutant tumors (pan-cancer: 3 . 2%, pancreatic: 7 . 6%, lung: 2 . 5%, biliary tract: 5 .4%) than in RB1 wild-type tumors (9 .9%, 18 . 7%, 16 . 1%, 16 .0%) . These ﬁndings were validated using the TCGA (n ¼ 9896) and GENIE (n ¼ 178 034) datasets. In lung adenocarcinoma, MTAP deletion was found in 22 .8% of EGFR-mutated tumors, 25 .0% of ALK-translocated tumors, and 20 .8% of ROS1-translocated tumors.  \nConclusions: MTAP deletion is associated with unique clinical and molecular features. These ﬁndings deﬁne the characteristics of MTAP-deleted cancers and provide a basis for synthetic lethal strategies in precision oncology. Key words: comprehensive genomic proﬁling, explainable artiﬁcial intelligence, MTAP, PRMT5, synthetic lethality  \nINTRODUCTION  \nMethylthioadenosine phosphorylase (MTAP) plays a crucial role in the methionine salvage pathway and contributes to the recycling of methylthioadenosine (MTA), a byproduct of polyamine synthesis, into methionine.1,2 Loss of the MTAP function, often through homozygous deletions, is frequently observed in various cancers.3 MTAP deletion has been implicated in promoting tumorigenesis; however, the exact  \n*Correspondence to: Dr Hiroaki Ikushima, Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655 Tokyo, Japan. Tel: ＋81-3-3815-5411  \nE-mail: [hikushima-tky@umin.ac.jp](hikushima-tky@umin.ac.jp) (H. Ikushima).  \n2059-7029/© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/","cbCair44yZqheeO5","https://ap.wps.com/l/cbCair44yZqheeO5","pdf",904492,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction\n## MTAP function and tumor relevance\n## PRMT5 activity and synthetic lethal rationale\n## Clinical development context and study motivation","[{\"question\":\"What is the main objective of this pan-cancer study?\",\"answer\":\"To comprehensively characterize the clinical and molecular profiles of MTAP-deleted tumors using nationwide and international comprehensive genomic datasets, enabling more precise PRMT5 inhibitor strategies.\"},{\"question\":\"How were MTAP deficiency predictors identified and validated?\",\"answer\":\"The study used machine learning and explainable AI on C-CAT clinico-genomic data, then validated and compared findings using TCGA and AACR GENIE datasets.\"},{\"question\":\"Which cancer types showed high prevalence of MTAP deletion?\",\"answer\":\"MTAP deletion was especially frequent in pancreatic cancer (18.4%), biliary tract cancer (15.6%), and lung cancer (14.3%).\"},{\"question\":\"What biological and therapeutic rationale connects MTAP deletion to PRMT5 inhibitors?\",\"answer\":\"Loss of MTAP leads to accumulation of MTA that binds PRMT5 and disrupts PRMT5 activity; preclinical work suggests MTAP-deleted cells are especially vulnerable to PRMT5 inhibition, supporting synthetic lethal approaches.\"}]","Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data - Original Article | PDF",1790182292,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/364126fcb3bb0b7e7950e0e0d57a70ba.webp",983,1269,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dcdb8d44ae0b147c21ad193c6333aff.webp",982,1268,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/979dfa1727ec218f92ef5a7fa2f7e63e.webp",981,1266,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82911e3ccccd4bb5d9d7a0b2e8542596.webp",980,1265]